Piramal Healthcare Settles Patent Litigation With Baxter Over Anesthetic
Piramal Healthcare reported yesterday that it has settled a patent litigation over Baxter Healthcare's anesthetic drug Suprane and could now launch its product in the U.S. market starting Jan. 1, 2014, according to a Business-Standard report.
Piramal Critical Care, a subsidiary of Piramal Healthcare, announced that patent litigation with Baxter Healthcare regarding generic anesthetic Suprane has been dismissed by the Delaware District Court pursuant to a settlement between the parties.
As per the terms of the agreement, both parties agreed that Piramal may launch its generic Desflurane in the United States as of Jan. 1, 2014, subject to regulatory approval.
Related Articles on Anesthesia:
Heat, Extreme Exercise Can Trigger Malignant Hyperthermia
Local Anesthesia Effective for Oculofacial Surgery
Elements of a Successful Anesthesia Service in ASCs
© Copyright ASC COMMUNICATIONS 2012. Interested in LINKING to or REPRINTING this content? View our policies by clicking here.
Latest Articles
- Distraction Reduces Perceived Pain
- Study: Nucynta Effective Pain Reliever for Diabetic Peripheral Neuropathy
- American Board of Internal Medicine Discusses Initiative to Limit Medical Tests
- Disciplinary Actions From State Medical Boards Increase
- Two Anesthesiologists Selected to Lead St. Joseph Medical Center Anesthesia Department
Dow Jones
Company ID [INDEXDJX:.DJI] Last trade:12,369.38 Trade time:4:03PM EDT Value change:▼73.11 (-0.59%)NASDAQ
Company ID [INDEXNASDAQ:.IXIC] Last trade:2,778.79 Trade time:5:16PM EDT Value change:▼34.90 (-1.24%)S&P 500
Company ID [INDEXSP:.INX] Last trade:1,295.22 Trade time:4:33PM EDT Value change:▼9.64 (-0.74%)Channels
